This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Forma Therapeutics Holdings Crecimiento futuro
Future controles de criterios 2/6
Información clave
9.2%
Tasa de crecimiento de los beneficios
22.1%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 24.8% |
| Tasa de crecimiento de los ingresos | 83.8% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Low |
| Última actualización | n/a |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
We're Keeping An Eye On Forma Therapeutics Holdings' (NASDAQ:FMTX) Cash Burn Rate
Aug 30
Forma Therapeutics GAAP EPS of -$1.10 misses by $0.11
Aug 05We're Hopeful That Forma Therapeutics Holdings (NASDAQ:FMTX) Will Use Its Cash Wisely
Mar 04We're Hopeful That Forma Therapeutics Holdings (NASDAQ:FMTX) Will Use Its Cash Wisely
Nov 20Here's Why We're Not Too Worried About Forma Therapeutics Holdings' (NASDAQ:FMTX) Cash Burn Situation
Aug 13We Think Forma Therapeutics Holdings (NASDAQ:FMTX) Needs To Drive Business Growth Carefully
Apr 18What Type Of Shareholders Own The Most Number of Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) Shares?
Jan 03Forma Therapeutics closes public offering priced at $45.25
Dec 16Forma Therapeutics prices equity offering at $45.25
Dec 11Forma Therapeutics' sickle cell treatment shows promising action at ASH presentation
Dec 08Forma Therapeutics EPS beats by $0.01
Nov 12Forma Therapeutics' sickle cell candidate an orphan drug in Europe
Nov 10Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2024 | 3 | -273 | N/A | N/A | 2 |
| 12/31/2023 | 9 | -218 | N/A | N/A | 2 |
| 12/31/2022 | 1 | -205 | N/A | N/A | 3 |
| 6/30/2022 | N/A | -190 | -175 | -170 | N/A |
| 3/31/2022 | N/A | -181 | -162 | -158 | N/A |
| 12/31/2021 | N/A | -173 | -154 | -150 | N/A |
| 9/30/2021 | N/A | -151 | -125 | -121 | N/A |
| 6/30/2021 | N/A | -136 | -113 | -112 | N/A |
| 3/31/2021 | N/A | -119 | -103 | -103 | N/A |
| 12/31/2020 | N/A | -74 | -96 | -95 | N/A |
| 9/30/2020 | 7 | -74 | -94 | -94 | N/A |
| 6/30/2020 | 11 | -78 | -95 | -95 | N/A |
| 3/31/2020 | 29 | -61 | -104 | -104 | N/A |
| 12/31/2019 | 101 | -53 | -35 | -34 | N/A |
| 12/31/2018 | 164 | 0 | -136 | -133 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: FMTX is forecast to remain unprofitable over the next 3 years.
Beneficios vs. Mercado: FMTX is forecast to remain unprofitable over the next 3 years.
Beneficios de alto crecimiento: FMTX is forecast to remain unprofitable over the next 3 years.
Ingresos vs. Mercado: FMTX's revenue (83.8% per year) is forecast to grow faster than the US market (7.2% per year).
Ingresos de alto crecimiento: FMTX's revenue (83.8% per year) is forecast to grow faster than 20% per year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if FMTX's Return on Equity is forecast to be high in 3 years time